Clinical trials: Lung Cancer Non-small Cell, open to volunteers
Lung Cancer (Non-Small Cell), Radiation
Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases
Primary Purpose:To preliminarily evaluate the efficacy and safety of recombinant human endostatin (Endostar) in the early prophylactic cohort (Cohort A) and late salvage cohort (Cohort B) for radiation-induced brain injury after…
- Conditions
- Lung Cancer (Non-Small Cell), Radiation, Brain Injury, Brain Edema
- Trial name
- NCT07841106
- Testing
- Recombinant Human Endostatin (Endostar)
- Volunteers
- 49 people
- Sponsor
- Jiangmen Central Hospital
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Insomnia in Patients With Metastatic Lung Cancer
This study evaluates how common insomnia (difficulties with sleep) is in patients with lung cancer that has spread from where it first started (primary site) to other places in the body.
- Trial name
- NCT06472804
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer, Triple Negative Breast Cancer
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies.
- Conditions
- Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06150664
- Testing
- CTX-8371
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- Compass Therapeutics
Non-small Cell Lung Cancer
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
A phase 3 study to evaluate the efficacy and safety of SY-3505 vs. crizotinib in patients with ALK-positive non-small cell lung cancer who had not received prior systemic therapy.
- Trial name
- NCT06254599
- Testing
- SY-3505 Capsules, Crizotinib Capsules
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Non-small Cell Lung Cancer (NSCLC)
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
All subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and including 10 years post last vaccine for those patients who are confirmed responders to the vaccine .
- Trial name
- NCT01720836
- Testing
- Vaccine + PolyICLC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Olivera Finn
Advanced Non-small Cell Lung Cancer
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II…
- Trial name
- NCT06585059
- Testing
- TQB2928 injection + Almonertinib Mesilate Tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have…
- Conditions
- Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer NSCLC, Non Small Cell Lung Carcinoma
- Trial name
- OMAE (NCT07563205)
- Where
- 16 sites in France
- Volunteers
- 100 people
- Sponsor
- GFPC Investigation
Lung Cancer, Nonsmall Cell
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
- Trial name
- NCT06319950
- Testing
- Furmonertinib, Osimertinib
- Volunteers
- 255 people
- Sponsor
- Taizhou Hospital
DFS
A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
A prospective, multicenter clinical study designed to explore the efficacy of adaptive therapy based on MRD status in patients with stage II-III non-small cell lung cancer(NSCLC) after treatment.
- Trial name
- NCT06524518
- Testing
- Chemotherapy combined with immunization
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Xuanwu Hospital, Beijing
Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers…
- Conditions
- Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, Non-Small Cell Lung Cancer
- Trial name
- NCT06699979
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Central South University
Lung Cancer (Non-Small Cell)
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Study Design: a Phase II, single-arm, multicenter, prospective, interventional study. Target Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor…
- Trial name
- NCT07198841
- Testing
- IBI351 combined with cetuximab β
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Guangdong Association of Clinical Trials
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma
- Trial name
- NCT05098210
- Testing
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Small Cell Lung Cancer With EGFR Mutation
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally…
- Trial name
- NCT06668103
- Testing
- ABSK043 in combination with Firmonertinib
- Where
- 5 sites in China
- Volunteers
- 54 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Non Small Cell Lung Cancer
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
Lung cancer is the most common neoplastic disease globally, with over 2 million new cases annually, accounting for 11.6% of all cancer diagnoses. It remains the leading cause of cancer-related deaths.
- Trial name
- METLUNG (NCT05445791)
- Testing
- Metformin Hydrochloride
- Where
- Mexico
- Volunteers
- 312 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
This prospective study aims to investigate whether the time of day when immune checkpoint inhibitors (ICIs) are administered affects the efficacy of neoadjuvant immunotherapy in patients with resectable stage II-III non-small…
- Trial name
- LungTime-C02 (NCT07251582)
- Testing
- Time of Day-based Assignment for Infusion of Immune Checkpoint Inhibitor (e.g., toripalimab, or pembrolizumab) + platinum-based chemotherapy
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Hunan Province Tumor Hospital
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer.
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT05136846
- Testing
- Carboplatin, Durvalumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer
TROP2 NMR Concordance Study
This is a two-stage, multi-center study to compare concordance of Local solution and Mixed solution with a Reference solution in testing TROP2 NMR in untreated advanced NSCLC patients, as well as clinical application and…
- Trial name
- NCT07624318
- Testing
- Reference solution, Mixed solution, Local solution
- Where
- 4 sites in China
- Volunteers
- 3,400 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than…
- Conditions
- Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT04892953
- Testing
- Carboplatin, Durvalumab, Gemcitabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.